320 related articles for article (PubMed ID: 36765891)
1. Helper Innate Lymphoid Cells-Unappreciated Players in Melanoma Therapy.
Garofalo C; Cerantonio A; Muscoli C; Mollace V; Viglietto G; De Marco C; Cristiani CM
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765891
[TBL] [Abstract][Full Text] [Related]
2. Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer.
Calvi M; Di Vito C; Frigo A; Trabanelli S; Jandus C; Mavilio D
Front Immunol; 2022; 13():914266. PubMed ID: 35720280
[TBL] [Abstract][Full Text] [Related]
3. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
4. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
Front Immunol; 2019; 10():910. PubMed ID: 31105707
[TBL] [Abstract][Full Text] [Related]
5. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
[TBL] [Abstract][Full Text] [Related]
6. Dichotomous Regulation of Acquired Immunity by Innate Lymphoid Cells.
Ebihara T
Cells; 2020 May; 9(5):. PubMed ID: 32403291
[TBL] [Abstract][Full Text] [Related]
7. CPHEN-15: Comprehensive phenotyping of human peripheral blood helper-ILCs by flow cytometry.
Del Zotto G; Vacca P; Moretta L; Quatrini L
Cytometry A; 2023 May; 103(5):378-382. PubMed ID: 36708139
[TBL] [Abstract][Full Text] [Related]
8. The Metabolic Basis of ILC Plasticity.
Pelletier A; Stockmann C
Front Immunol; 2022; 13():858051. PubMed ID: 35572512
[TBL] [Abstract][Full Text] [Related]
9. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Cristiani CM; Capone M; Garofalo C; Madonna G; Mallardo D; Tuffanelli M; Vanella V; Greco M; Foti DP; Viglietto G; Ascierto PA; Spits H; Carbone E
Front Immunol; 2022; 13():811131. PubMed ID: 35173725
[TBL] [Abstract][Full Text] [Related]
10. The role of ILC subsets in cancer.
Bruchard M; Spits H
Semin Immunol; 2022 Nov; 61-64():101654. PubMed ID: 36306660
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA-seq identifies a PD-1
Yu Y; Tsang JC; Wang C; Clare S; Wang J; Chen X; Brandt C; Kane L; Campos LS; Lu L; Belz GT; McKenzie AN; Teichmann SA; Dougan G; Liu P
Nature; 2016 Nov; 539(7627):102-106. PubMed ID: 27749818
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells.
Munari E; Quatrini L; Ciancaglini C; Eccher A; Bogina G; Moretta L; Mariotti FR
Semin Immunol; 2022 Nov; 61-64():101660. PubMed ID: 36370672
[TBL] [Abstract][Full Text] [Related]
13. Developmental options and functional plasticity of innate lymphoid cells.
Lim AI; Verrier T; Vosshenrich CA; Di Santo JP
Curr Opin Immunol; 2017 Feb; 44():61-68. PubMed ID: 28359987
[TBL] [Abstract][Full Text] [Related]
14. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
Vacca P; Munari E; Tumino N; Moretta F; Pietra G; Vitale M; Del Zotto G; Mariotti FR; Mingari MC; Moretta L
Immunol Lett; 2018 Sep; 201():14-19. PubMed ID: 30439479
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of Innate Lymphoid Cells in Cancer.
Heinrich B; Korangy F
Front Immunol; 2022; 13():886520. PubMed ID: 35663967
[TBL] [Abstract][Full Text] [Related]
16. Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?
Tumino N; Vacca P; Quatrini L; Munari E; Moretta F; Pelosi A; Mariotti FR; Moretta L
Front Immunol; 2019; 10():3140. PubMed ID: 32063901
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.
Eken A; Yetkin MF; Vural A; Okus FZ; Erdem S; Azizoglu ZB; Haliloglu Y; Cakir M; Turkoglu EM; Kilic O; Kara I; Dönmez Altuntaş H; Oukka M; Kutuk MS; Mirza M; Canatan H
Front Immunol; 2019; 10():217. PubMed ID: 30828332
[TBL] [Abstract][Full Text] [Related]
18. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
[TBL] [Abstract][Full Text] [Related]
19. NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma.
Garofalo C; De Marco C; Cristiani CM
Front Oncol; 2021; 11():754541. PubMed ID: 34712615
[TBL] [Abstract][Full Text] [Related]
20. Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes.
Rethacker L; Boy M; Bisio V; Roussin F; Denizeau J; Vincent-Salomon A; Borcoman E; Sedlik C; Piaggio E; Toubert A; Dulphy N; Caignard A
Oncoimmunology; 2022; 11(1):2057396. PubMed ID: 35371620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
